Document is current
Any future updates will be listed below
-
Authors
Gaccioli, Francesca https://orcid.org/0000-0001-7178-8921
Stephens, Katie https://orcid.org/0000-0002-1255-2641
Sovio, Ulla https://orcid.org/0000-0002-0799-1105
Jessop, Flora
Wong, Hilary S.
Lager, Susanne https://orcid.org/0000-0003-3556-065X
Cook, Emma https://orcid.org/0000-0002-6142-4443
de Goffau, Marcus C.
Le Doare, Kirsty
Peacock, Sharon J. https://orcid.org/0000-0002-1718-2782
Parkhill, Julian https://orcid.org/0000-0002-7069-5958
Charnock-Jones, D. Stephen https://orcid.org/0000-0002-2936-4890
Smith, Gordon C. S. https://orcid.org/0000-0003-2124-0997
-
Funding
Funding for this research was provided by:
RCUK | Medical Research Council (MR/K021133/1)
RCUK | Medical Research Council (MR/K021133/1)
RCUK | Medical Research Council (MR/K021133/1)
RCUK | Medical Research Council (MR/K021133/1)
RCUK | Medical Research Council (MR/K021133/1)
RCUK | Medical Research Council (MR/K021133/1)
RCUK | Medical Research Council (MR/K021133/1)
DH | National Institute for Health Research
Wellcome Trust
- License Information
-
More Information
Article History
Received: 23 June 2023
Accepted: 16 October 2023
First Online: 29 November 2023
Competing interests
: G.C.S.S. and D.S.C.-J. receive research funding from Pfizer Bacterial Vaccines for studies on the relationship between placental GBS DNA and maternal circulating levels of GBS antibodies. Cambridge Enterprise (United Kingdom) has filed a patent relating to the primers and probe used in the nested PCR–qPCR assay described in this paper with F.G., M.C.d.G., D.S.C.-J. and G.C.S.S. as the named inventors. The competing interests outside the area of the submitted work are as follows: J.P. reports grants from Pfizer and personal fees from Next Gen Diagnostics LLC; S.J.P. reports personal fees from Specific and personal fees from Next Gen Diagnostics; G.C.S.S. and D.S.C.-J. report grants from GlaxoSmithKline Research and Development Limited, grants and non-financial support from Roche Diagnostics Ltd and non-financial support from Illumina Inc; G.C.S.S. reports personal fees from GlaxoSmithKline Research and Development Limited; K.L.D. is an adviser for Pfizer, Minervax and GSK for GBS vaccines; and K.S., U.S., F.J., H.S.W., S.L. and E.C. declare no competing interests.
